key: cord-0920110-j3hsyo8h
authors: Bjork, J.A.; Wallace, K.B.
title: Remdesivir; molecular and functional measures of mitochondrial safety
date: 2021-11-02
journal: Toxicol Appl Pharmacol
DOI: 10.1016/j.taap.2021.115783
sha: 2de3da0ac2c0de173117374eeb36de841748ccf5
doc_id: 920110
cord_uid: j3hsyo8h

Remdesivir is one of a few antiviral drugs approved for treating severe cases of coronavirus 2 (SARS-CoV-2) infection in hospitalized patients. The prodrug is a nucleoside analog that interferes with viral replication by inhibiting viral RNA-dependent RNA polymerase. The drug has also been shown to be a weak inhibitor of human mitochondrial RNA polymerase, leaving open the possibility of mitochondrial off-targets and toxicity. The investigation was designed to explore whether remdesivir causes mitochondrial toxicity, using both genomic and functional parameters in the assessment. Human-derived HepG2 liver cells were exposed for up to 48 h in culture to increasing concentrations of remdesivir. At sub-cytotoxic concentrations (<1 μM), the drug failed to alter either the number of copies or the expression of the mitochondrial genome. mtDNA copy number was unaffected as was the relative rates of expression of mtDNA-encoded and nuclear encoded subunits of complexes I and IV of the mitochondrial respiratory chain. Consistent with this is the observation that remdesivir was without effect on mitochondrial respiration, including basal respiration, proton leak, maximum uncoupled respiration, spare respiratory capacity or coupling efficiency. We conclude that although remdesivir has weak inhibitory activity towards mitochondrial RNA polymerase, mitochondria are not primary off-targets for the mechanism of cytotoxicity of the drug.

Remdesivir (Veklury ® , Gilead Sciences) is a phosphoramidate substituted nucleotide analog that is incorporated by RNA-dependent RNA polymerase into and truncates replication of viral RNA.

The drug possesses potent and broad spectrum antiviral activity, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Agostini et al., 2018) . Based on recent favorable clinical trials (Beigel et al., 2020; Goldman et al., 2020; Spinner et al., 2020) , the drug was approved by the U.S. FDA in 2020 for the treatment of hospitalized patients 12 years of age and older and weighing at least 40 kg with severe COVID-19 (Grein et al., 2020) .

Remdesivir (RDV) is a prodrug and when administered to mammals is hydrolyzed to the monophosphate metabolite, which is subsequently phosphorylated to the pharmacologically active adenosine triphosphate analog (RDV-TP). This phosphorylated nucleoside analog is recognized as a substrate for RNA-dependent RNA polymerase and is incorporated into and inhibits replication of the viral RNA (Tchesnokov et al., 2019) . As a result, RDV-TP interrupts by truncating the synthesis of the viral genome, including that of SARS-CoV-2 (Gordon et al., 2020) .

The critical factor that endows RDV its specificity as an antiviral agent is that the phosphorylated nucleoside analog is a favorable substrate for viral but not human mitochondrial RNA polymerase (Tchesnokov et al., 2019; Warren et al., 2016) . The dissociation constants (Km) for RDV inhibiting Ebola virus, respiratory syncytial virus and human mitochondrial RNA polymerase are 5.7 µM, 0.5 µM, and 21 µM, respectively (Tchesnokov et al., 2019) . Preclinical safety studies with a broad panel of 87 cellular and biochemical assays demonstrated that clinically relevant and non-cytotoxic concentrations of RDV and its J o u r n a l P r e -p r o o f monophosphorylated analog have minimal off-target effects in numerous primary and transformed human cells lines (Xu et al., 2021) .

Being a nucleoside analog, however, raises concerns regarding the well-established clinical history of mitochondrial toxicity associated with nucleoside analog antiviral drugs (Kakuda, 2000) . This concern is exemplified by the nucleoside analog reverse transcriptase inhibitors (NARTIs) effective in limiting replication of the AIDS virus. In addition to truncating the viral genome, these NARTIs also inhibit mitochondrial gene replication leading to mitochondrial depletion and metabolic dysfunction in affected patients (Fosslien, 2001; Simpson et al., 1989) .

Being an analog of ATP, the phosphorylated metabolite of RDV may also interfere with adenine nucleotide-dependent metabolic regulation, including mitochondrial oxidative phosphorylation (Feng, 2018; Lund and Wallace, 2004a; b) . In light of the growing concerns for mitochondrial off-targets of drug action (Wallace and Starkov, 2000) , we investigated the potential hazard of RDV causing depletion of the mitochondrial genome or transcriptome and/or deficits in mitochondrial function that could possibly compromise the clinical efficacy of this drug in treating critical COVID-19 positive patients.

METHODS -Cell Culture -The human hepatoma cell line HepG2/C3A was purchased from American Tissue Culture Collection (ATCC; Manassas, VA) and grown in 75 cm 2 flasks with Eagle's Minimum Essential Media (EMEM) supplemented with 10% fetal bovine serum (FBS) at 37 o C in a humidified atmosphere of 5%CO 2 . Each replicate was a culture started from a single vial of frozen cells, with a passage number between 9 and 10 from original stock. For SRB, mtDNA copy number, and RT-qPCR assays, cells were passaged to 24-well tissue culture plates J o u r n a l P r e -p r o o f at 80% confluence and allowed to attach overnight. For mitochondrial function assay the cells were passaged to 96-well Seahorse Bioscience® XF96 cell culture plates at a density of 40K cells per well.

Chemical exposure -Remdesivir was purchased form Cayman Chemicals (Item no. 30354) as the monophosphoramidate prodrug and 1000 stock solutions were prepared in anhydrous DMSO. Remdesivir stock was diluted in growth media and serial dilutions made such that the concentration of DMSO was 0.1% in all dilutions. On the day of exposure, the media was removed from each well and replaced with treated media and the cells incubated for 24 to 72 hours.

Cytotoxicity -To establish an appropriate does range for RDV, cell killing was measured by sulphorhodamine B (SRB) binding assay (Skehan P. et al. 1990 ). Cells were seeded at 50% confluence on 24-well culture plates. After exposure, the cells were washed twice with PBS then fixed with ice cold 1% acetic acid in methanol for 30 minutes. The plate was then rinsed with 1% acetic acid and stained with 0.5% SRB in 1% acetic acid for 30 minutes. The SRB stain was discarded and the plate was rinsed with 1% acetic acid until the wash was clear. After air drying, the bound SRB was solubilized in 10 mM Tris Base and the absorbance measured at 540 Seahorse 96-well culture plates were exposed to RDV in EMEM growth media or 24 and 48 hours respectively. On the day of the assay, the media was replaced with Seahorse XF DMEM Medium, pH 7.4 (Agilent, 103575-100) containing 5 mM HEPES, 10 mM glucose, 1 mM sodium pyruvate, and 2 mM l-glutamine and equilibrated in a non-CO 2 , 37 C incubator for 30 minutes prior to starting the assay. The Seahorse Cell Mito Stress Test assay consisted of sequential additions of optimized concentrations of oligomycin (2 M), FCCP (2 M) and rotenone/antimycin A (0.5 M) recording the rate of oxygen consumption between intervals of addition. Parameter calculations were made using the Seahorse XF Cell Mito Stress Test Report Generator application ( Fig. 4 ; Agilent).

RT-qPCR -Gene expression was measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). After exposure, the cells were washed with phosphate buffered saline (PBS) and total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). 350 l lysis buffer was added directly to each well and the plate mixed by vortex. The cell lysate was homogenized with 5 passes through a 27-gauge needle fitted to a tuberculin syringe and transferred to the gDNA eliminator spin column provided in the kit. Washing and centrifugation steps were (Table 1) were designed using the National Center for Biotechnology Information (NCBI) Primer-Blast application (Ye, Coulouris et al. 2012) . Quantification was made against a five-point, ten-fold serial dilution of gene target specific PCR product. 2'-C-methyladeonsoine

(2-C-MA; Santa Cruz Biotechnology) was included as a positive control for inhibiting mitochondrial RNA Polymerase. J o u r n a l P r e -p r o o f (Malik et al., 2011) . As demonstrated, mtDNA copy number for HepG2 cells was between 5-25 for all concentrations of RDV at both 24 and 48 hr; there was no statistically significant treatment effect. It is noteworthy that mtDNA copy number was consistently higher at 24hr compared to 48hr for all treatments, which we attribute to possibly dilution bias regarding mtDNA as described by Malik et al. (Malik et al., 2011) . Regardless, the results demonstrate that RDV, under these exposure conditions, does not interfere with mitochondrial DNA replication in HepG2 cells in culture, even at the cytostatic or cytotoxic concentration of 10 µM.

Conversely, the positive control 2', 3' -dideoxycytidine (ddC) caused significant mtDNA depletion at the noncytotoxic concentration of 40 nM (panel 2B).

Similarly, we found no evidence that RDV interferes with mitochondrial gene transcription under these conditions (Figure 3 ). This contrasts with the results for the positive control 2-C-MA, which at 25 µM inhibited mitochondria-specific gene expression at noncytotoxic concentrations (Ddit3 gene expression). The criteria we employed as a measure of mitochondrial transcription was a treatment-related effect on the ratio of RT-qPCR quantified transcripts for genes encoded by the mitochondrial versus nuclear genomes using two paired gene sets ND2/NDUFB3 and COX2/COX5B; ND2 and COX2 being mitochondrial encoded genes of respiratory complexes I and IV, respectfully and NDUFB3 and COX5B being encoded by the nuclear genome. For this set of experiments, we conducted a second preliminary study to exclude cytotoxicity as a potential contributing factor by quantitative PCR of the DNA damage inducible transcript 3 (DDIT3) gene transcript, which is part of the unfolded protein response to ER stress. Ddit3 is induced under conditions of severe cellular stress (Los et al., 1999;  J o u r n a l P r e -p r o o f Journal Pre-proof Oyadomari and Mori, 2004) and we have used this transcript previously as a sensitive and specific quantifiable measure of early cell injury (Bjork and Wallace, 2009 ). The results for the time and dose dependent cytotoxicity measured with the DDIT3 transcript (Fig. 3A) is consistent with that observed using the SRB assay (Fig. 1) ; 5 µM RDV caused significant cytotoxicity and was not considered when evaluating the direct effects of the drug. The increase in Ddit3 gene expression with 1 µM RDV was increased slightly, but was not statistically significant with an n=3 samples.

Viewing the individual gene transcripts (Fig. 3 , panels B-E), RDV failed to alter the quantitative expression of the mitochondrial encoded genes at any concentration and effected the nuclear encoded genes only at a 5µM concentration, which is cytotoxic to the cells (Fig. 3A) . Likewise, the ratio of mitochondrial to nuclear encoded gene transcripts ( Fig. 3F and 3G) was not altered by concentrations of RDV that were not also cytotoxic to the cells.

Our final objective, despite having no effect on mitochondrial gene replication or expression, was to examine if RDV at these same concentrations alters mitochondrial function, employing the Seahorse® XF96 (Beeson et al., 2010; Nadanaciva et al., 2012 ) Extracellular Flux Analyzer technology for measuring whole cell oxygen consumption rate under various conditions. Figure   4 illustrates the conduct of this assay along with the method of calculation for each reported parameter. This figure serves as reference for interpreting the results reported in Figure 5 for the dose-dependent effect of RDV on cellular respiration at 48 hr of exposure. What was observed is that RDV failed to significantly alter any of the respiratory parameters at J o u r n a l P r e -p r o o f concentrations of 0.5µM or less. It was only at concentrations that approached or caused significant cytotoxicity (1µM and 5µM; Figure 1 ) that RDV had a significant effect on suppressing mitochondrial respiration. Similar results were observed after 24 hours of exposure to 5 µM RDV; However, 1 µM RDV did not alter mitochondrial respiration at this earlier time point (data not shown). The fact that all measured parameters were suppressed at high concentrations of RDV suggests a generalized decrement of mitochondrial respiration that was likely secondary to cell morbidity and not specific to the molecular mechanism of RDV toxicity.

inhibition of SARS-CoV-2 corona virus and was approved in 2020 as an effective antiviral agent for treating hospitalized patients 12 years and older and weighing at least 40 kg infected with the COVID-19 virus (Grein et al., 2020) . The phosphorylated nucleoside metabolite of RDV is mistakenly recognized by viral RNA-dependent RNA polymerase (Gordon et al., 2020) , which is essential for replicating the viral genome. As a result, the elongating RNA strand is truncated and viral replication halted. The drug has been undergone clinical testing including phase III clinical trials with few reported minor adverse events, most frequently an elevation in serum aminotransferase enzymes (Beigel et al., 2020; Goldman et al., 2020; Spinner et al., 2020) , which some have attributed to the viral infection itself.

The concern that RDV might produce adverse clinical events due to a lack of specificity towards RNA-dependent RNA polymerase has been addressed in-part previously. The drug has been demonstrated to inhibit purified human mitochondrial RNA polymerase, but only at J o u r n a l P r e -p r o o f concentrations more than 100-fold in excess of that required to inhibit Ebola or RSV RNAdependent RNA polymerase (Tchesnokov et al., 2019) . Xu and coworkers (Xu et al., 2021) conducted an extensive in vitro screen of potential off-target assays, some of which were mitochondrial, in characterizing the preclinical toxicity of RDV. Their format was a panel of 87 high throughput cellular and biochemical assays across 8 different human cell types. What they found was that the concentration of cellular ATP decreased after 5 days of continuous exposure to RDV, the 50% effective concentration (EC 50 ) ranging between 2-20 µM RDV for the individual cell types. Associated with this was a decrease in spare respiratory capacity, as measured by Seahorse XF Flux analyzer, at concentrations exceeding 1µM after 3 days RDV exposure, which the authors attribute not to a primary mitochondrial effect, but rather to a generalized cytotoxicity. This is further supported by the lack of any observed effect of RDV on mtDNA copy number, measured by qPCR, or protein synthesis measured by western blot. The authors conclude that, overall, there was a lack of a specific effect of RDV on cellular respiration among the four cell systems examined (Xu et al., 2021) .

The results presented in this investigation are targeted specifically to effects of RDV on mitochondria and are consistent with and substantively extend the findings published by Xu et al. (Xu et al., 2021) . First, using both the SRB assay as well as the more sensitive and specific measure of Ddit3 gene expression, we find that the EC 50 for cytotoxicity for HepG2/3CA cells (1-10 µM RDV for 2-3 days) is in the same range as that reported by Xu et al. using ATP luminescence as a measure of viability for this same cell line (3.7 µM at 5 days). We also J o u r n a l P r e -p r o o f confirm the observation that, using qPCR but with different gene targets, the nucleoside analog does not alter mtDNA copy number in HepG2 cells.

Xu and coworkers demonstrate that the EC 50 of RDV for affecting the concentration of mtDNAencoded cytochrome oxidase subunit I (COX-I) protein is not different from that for the nuclearencoded SDH-A, which they interpret as the drug not preferentially inhibiting mitochondrial protein synthesis, i.e., gene translation (Xu et al., 2021) . In the present investigation we extend this observation by demonstrating that at sub-cytotoxic concentrations RDV also fails to inhibit mitochondrial gene transcription. This is reflected by the relative expression of mitochondrial genes encoding subunits for either of two complexes of the electron transport chain, complex I (NDH) and complex IV (COX). This lack of effect of RDV on mtDNA transcription is a more direct measure than is mitochondrial protein synthesis for mtRNA polymerase activity.

Of perhaps greatest significance is the observation that RDV, under the conditions employed, does not alter mitochondrial respiratory function. Xu and coworkers using the Seahorse Extracellular Flux Analyzer technology reported that RDV does not alter spare respiratory capacity in HepG2 cells (Xu et al., 2021) . We expanded this observation to demonstrate that RDV, at concentrations that did not alter cell viability, did not alter any of the parameters associated with cell respiration in this human hepatic cell line. This included not only spare respiratory capacity, but also basal respiration, ATP production, proton leak, maximum respiration, non-mitochondrial respiration and coupling efficiency. An exception is 1 µM RDV, which caused aa increase in Ddit3 gene expression that was not statiscally significant with 3 J o u r n a l P r e -p r o o f sample replicates. Although this might be interpreted that RDV interferes with mitochondrial respiration at non-cytotoxic concentrations, it is also possible that at 1 µM RDV the cells are stressed but not to the point of statistical significance. At 24 hr 1 µM RDV did not interfere with cell respiration (data not shown). The lack of an effect of RDV on hepatic cell respiration is consistent with the absence of an effect of the drug on the mitochondrial genome (gene dose or expression). From this we conclude that despite being a nucleoside analog that is a potent inhibitor of RNA polymerase, this activity is specific in sparing the mitochondria as demonstrated by Tchesnokov et al. (Tchesnokov et al., 2019) . Xu et al demonstrated that RDV has greater cytotoxic and mitochondrial potency in HepG2 cells than the parent nucleoside or nucleoside triphosphate (Xu et al., 2021) , indicating that the lack of activity observed with RDV is not due to a lack metabolic activation of the prodrug. Thus, we conclude that remdesivir does not cause mitochondrial toxicity and that the cytotoxicity that is observed occurs by a mechanism that does not involve mitochondrial genomic or functional features as primary molecular off-targets. were measured for HepG2 cells exposed to increasing concentrations of remdesivir for 48 hrs. Each panel represents a parameter calculated according to the formula listed in Figure 4 and each bar reflects the mean +/-S.D. for 4 independent experimental observations. Asterisks (*) indicate a statistically significant difference compared to the zero remdesivir control (Dunnett's, p<0 .05).

Highlights  Remdesivir is cytotoxic to HepG2 cells at concentrations > 1µM.  At non-cytotoxic concentrations remdesivir fails to alter mitochondrial DNA copy number.  Remdesivir does not inhibit mitochondrial gene expression at non-cytotoxic concentrations.  Remdesivir does not interfere with mitochondrial respiration at concentrations that are not cytotoxic.  Thus, the cytotoxicity observe with remdesivir does not involve primary mitochondrial offtargets. 

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

A high-throughput respirometric assay for mitochondrial biogenesis and toxicity

Remdesivir for the Treatment of Covid-19 -Final Report

Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures

Multiple Comparison Procedure for Comparing Several Treatments with a Control

Addressing the selectivity and toxicity of antiviral nucleosides

Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitorinduced mitochondrial toxicity

Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer

Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics

Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics

Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias

Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform

Roles of CHOP/GADD153 in endoplasmic reticulum stress

Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Mitochondrial targets of drug toxicity

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent

At the end of the exposure the cells were fixed with methanol and stained with sulphorhodamine B (SRB). The bound SRB was solubilized in 10 mM Tris bass and the absorbance measured 540nm

B) HepG2 cells were exposed to sub-cytotoxic concentration of 2', 3' -dideoxycytidine (40 nM ddC) for 48 hours as a positive control for mtDNA depletion. The values are expressed as mtDNA/nDNA copies and expressed as the mean +/-S.D. for 3 independent measures

This work was supported in-part by an unrestricted research grant from the 3M Company. 3M Company did not contribute to the study concept or participate in any part of the experimental design, data analysis and interpretation, or in preparation of this manuscript.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests